Search research articles
Contact Us
Filters
Showing results (261-270 of 493) with videos related to
Page
of 50
Sort By:
Behaviour Research and Therapy
|
June 28, 2017
Departing from the essential features of a high quality systematic review of psychotherapy: A response to Öst (2014) and recommendations for improvement
Paul W B Atkins, Joseph Ciarrochi, Brandon A Gaudiano, et al.
Journal of Translational Medicine
|
December 23, 2011
High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma
Xiaoen Wang, Liang Zhang, S Nahum Goldberg, et al.
Cancers
|
September 23, 2022
Correction: Zhang et al. Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. <i>Cancers</i> 2021, <i>13</i>, 6109
Dongyu Zhang, Neil J Shah, Michael Cook, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy
|
February 1, 1994
Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma
K Margolin, F R Aronson, M Sznol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 17, 2015
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804)
Keith T Flaherty, Judith B Manola, Michael Pins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 1993
Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma
M B Atkins, J Sparano, R I Fisher, et al.
Cancer Research
|
May 4, 2021
Targeting DDX3X Triggers Antitumor Immunity via a dsRNA-Mediated Tumor-Intrinsic Type I Interferon Response
Hyeongjwa Choi, Juntae Kwon, Min Soon Cho, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
August 2, 2007
Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics
Michael B Atkins, David Carbone, George Coukos, et al.
Urologic Oncology
|
February 5, 2017
Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK.Cancer. 2015 Oct 1;121(19):3435-43. [Epub 2015 Jun 8]. doi: 10.1002/cncr.29503
Raman Jay, R R McKay, L Werner, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 15, 1999
Amplification and overexpression of peroxisome proliferator-activated receptor binding protein (PBP/PPARBP) gene in breast cancer
Y Zhu, C Qi, S Jain, et al.
Page
of 50
Search research articles
Search
Showing results (261-270 of 493) with videos related to
Sort By:
Page
of 50
Behaviour Research and Therapy
|
June 28, 2017
Departing from the essential features of a high quality systematic review of psychotherapy: A response to Öst (2014) and recommendations for improvement
Paul W B Atkins, Joseph Ciarrochi, Brandon A Gaudiano, et al.
Journal of Translational Medicine
|
December 23, 2011
High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma
Xiaoen Wang, Liang Zhang, S Nahum Goldberg, et al.
Cancers
|
September 23, 2022
Correction: Zhang et al. Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. <i>Cancers</i> 2021, <i>13</i>, 6109
Dongyu Zhang, Neil J Shah, Michael Cook, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy
|
February 1, 1994
Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma
K Margolin, F R Aronson, M Sznol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 17, 2015
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804)
Keith T Flaherty, Judith B Manola, Michael Pins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 1993
Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma
M B Atkins, J Sparano, R I Fisher, et al.
Cancer Research
|
May 4, 2021
Targeting DDX3X Triggers Antitumor Immunity via a dsRNA-Mediated Tumor-Intrinsic Type I Interferon Response
Hyeongjwa Choi, Juntae Kwon, Min Soon Cho, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
August 2, 2007
Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics
Michael B Atkins, David Carbone, George Coukos, et al.
Urologic Oncology
|
February 5, 2017
Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK.Cancer. 2015 Oct 1;121(19):3435-43. [Epub 2015 Jun 8]. doi: 10.1002/cncr.29503
Raman Jay, R R McKay, L Werner, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 15, 1999
Amplification and overexpression of peroxisome proliferator-activated receptor binding protein (PBP/PPARBP) gene in breast cancer
Y Zhu, C Qi, S Jain, et al.
Page
of 50